Cogent Biosciences (COGT) Competitors $16.02 +0.59 (+3.79%) As of 11:08 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock COGT vs. MRUS, RNA, GRFS, CYTK, RYTM, ABVX, CRSP, NUVL, AXSM, and LEGNShould you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Merus (MRUS), Avidity Biosciences (RNA), Grifols (GRFS), Cytokinetics (CYTK), Rhythm Pharmaceuticals (RYTM), Abivax (ABVX), CRISPR Therapeutics (CRSP), Nuvalent (NUVL), Axsome Therapeutics (AXSM), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. Cogent Biosciences vs. Its Competitors Merus Avidity Biosciences Grifols Cytokinetics Rhythm Pharmaceuticals Abivax CRISPR Therapeutics Nuvalent Axsome Therapeutics Legend Biotech Merus (NASDAQ:MRUS) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation. Do institutionals & insiders believe in MRUS or COGT? 96.1% of Merus shares are owned by institutional investors. 3.7% of Merus shares are owned by insiders. Comparatively, 7.3% of Cogent Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, MRUS or COGT? Merus has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Is MRUS or COGT more profitable? Cogent Biosciences has a net margin of 0.00% compared to Merus' net margin of -685.64%. Merus' return on equity of -50.28% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Merus-685.64% -50.28% -42.00% Cogent Biosciences N/A -223.82%-89.44% Does the media favor MRUS or COGT? In the previous week, Merus had 6 more articles in the media than Cogent Biosciences. MarketBeat recorded 11 mentions for Merus and 5 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.56 beat Merus' score of -0.26 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Merus 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Neutral Cogent Biosciences 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer MRUS or COGT? Merus currently has a consensus price target of $93.12, indicating a potential downside of 1.87%. Cogent Biosciences has a consensus price target of $20.00, indicating a potential upside of 24.88%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cogent Biosciences is more favorable than Merus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Merus 1 Sell rating(s) 14 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.16Cogent Biosciences 1 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.77 Which has better earnings & valuation, MRUS or COGT? Merus has higher revenue and earnings than Cogent Biosciences. Merus is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMerus$36.13M198.64-$215.33M-$5.50-17.25Cogent BiosciencesN/AN/A-$255.86M-$1.78-9.00 SummaryCogent Biosciences beats Merus on 9 of the 16 factors compared between the two stocks. Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COGT vs. The Competition Export to ExcelMetricCogent BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.82B$3.39B$6.06B$10.57BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-8.9822.7385.0727.47Price / SalesN/A268.36518.67200.70Price / CashN/A46.9537.5761.53Price / Book12.1310.5412.336.87Net Income-$255.86M-$52.58M$3.32B$276.69M7 Day Performance2.79%0.74%0.70%0.70%1 Month Performance29.05%15.64%10.27%8.83%1 Year Performance37.23%18.08%74.67%36.06% Cogent Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COGTCogent Biosciences2.1959 of 5 stars$16.02+3.8%$20.00+24.9%+36.4%$1.82BN/A-8.9880MRUSMerus0.8806 of 5 stars$94.270.0%$93.12-1.2%+81.8%$7.13B$56.23M-17.1437RNAAvidity Biosciences1.9744 of 5 stars$46.18-1.7%$68.32+47.9%+3.0%$6.86B$10.90M-12.97190GRFSGrifols3.7778 of 5 stars$9.61-3.4%$10.30+7.2%+11.7%$6.84B$7.81B8.2123,822CYTKCytokinetics3.6821 of 5 stars$60.64+6.4%$76.64+26.4%+12.0%$6.82B$18.47M-11.89250RYTMRhythm Pharmaceuticals3.1156 of 5 stars$97.86-1.2%$106.64+9.0%+109.4%$6.58B$156.29M-32.51140ABVXAbivax2.6653 of 5 stars$86.67+3.3%$103.29+19.2%+925.4%$6.34BN/A0.0061Analyst ForecastHigh Trading VolumeCRSPCRISPR Therapeutics1.7304 of 5 stars$70.19+3.6%$71.50+1.9%+45.1%$6.16B$35M-12.93460Analyst ForecastNUVLNuvalent2.7917 of 5 stars$83.85-0.4%$118.89+41.8%-18.0%$6.07BN/A-17.1140Analyst ForecastAXSMAxsome Therapeutics4.6956 of 5 stars$119.94-0.3%$177.93+48.4%+44.6%$6.00B$495.03M-23.66380Analyst RevisionLEGNLegend Biotech2.6249 of 5 stars$31.44-1.9%$74.22+136.1%-33.1%$5.92B$627.24M-35.732,609News Coverage Related Companies and Tools Related Companies Merus Alternatives Avidity Biosciences Alternatives Grifols Alternatives Cytokinetics Alternatives Rhythm Pharmaceuticals Alternatives Abivax Alternatives CRISPR Therapeutics Alternatives Nuvalent Alternatives Axsome Therapeutics Alternatives Legend Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COGT) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
